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ABSTRACT
Cytoplasmic ribonucleoprotein granules, known as
processing bodies (P-bodies), contain a common
set of conserved RNA-processing enzymes, and
mRNAs with AU-rich elements (AREs) are delivered
to P-bodies for translational silencing. Although the
dynamics of P-bodies is physically linked to cyto-
skeletal network, it is unclear how small GTPases
are involved in the P-body regulation and the
ARE-mRNA metabolism. We found here that
glucose depletion activates RhoA GTPase and
alters the P-body dynamics in HeLa cells. These
glucose-depleted effects are reproduced by the
overexpression of the RhoA-subfamily GTPases
and conversely abolished by the inhibition of RhoA
activation. Interestingly, both RhoA activation and
glucose depletion inhibit the mRNA accumulation
and degradation. These findings indicate that
RhoA participates in the stress-induced rearrange-
ment of P-bodies and the release of nucleated
ARE-mRNAs for their stabilization.
INTRODUCTION
The regulation of mRNA turnover plays a signiﬁcant role
in controlling gene expression. Recent studies have
identiﬁed that a number of proteins responsible for
mRNA decay are concentrated in cytoplasmic foci,
referred to as processing bodies (P-bodies) (1–5).
P-bodies are dynamic structures and represent pools of
non-translating messenger ribonucleoprotein particles
(mRNPs) (4–10) that play important roles not only in
mRNA storage (11) but also in mRNA decapping, 50–30
decay (4,5) and translational control (12). In addition to
mRNAs, P-bodies contain enzymes responsible for
decapping, deadenylation and 50–30 degradation such as
Dcp1/2, Ccr4 and Xrn1, along with decapping enhancers
and/or translational repressors including rck/p54 (Dhh1)
(1–4,13). Several proteins have been identiﬁed as key com-
ponents in the formation of P-bodies, as their depletion
leads to the disappearance of P-bodies in mammalian cells
(13,14).
The size and abundance of microscopically visible
P-bodies within cells are altered due to mutations that
reduce the rate of decapping or degradation of mRNAs
(4), suggesting that these structures are actively involved
in the regulation of mRNA decay pathways. Additionally,
mRNA molecules within P-bodies can return to poly-
somes for their translation (11). These results suggest
that cytoplasmic mRNAs shuttle in and out of P-bodies
and that their structural changes may affect the rates of
mRNA entry into, its decay within, and its exit from
P-bodies. Recent studies have also revealed that P-body
dynamics is physically linked to the intracellular microtu-
bule network (15,16). As well as microtubule disruption by
chemical reagents such as nocodazole, cell stress induced
by glucose depletion or osmotic shock results in a marked
increase in P-body abundance (9). However, the alteration
in P-body dynamics induces no applicable change in either
mRNA decay or global mRNA translation. It has not
been elucidated whether the smaller and larger aggregates
of P-bodies have compositional and/or functional differ-
ences during the process of mRNA metabolism.
Furthermore, little is known about the molecular mechan-
isms by which P-bodies are assembled or disassembled and
how they are rearranged under various cell conditions.
In the last decade, speciﬁc pathways of mRNA turnover
have been identiﬁed, and these can be controlled to
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which are repeats of the nucleotide sequence AUUUA, are
found in the 30-untranslated region of many human
mRNAs that undergo translational silencing and rapid
turnover, a number of which encode interleukins, cyto-
kines and proto-oncogenes (17–22). ARE sequences
serve as binding sites for trans-acting factors that
regulate the translation and stability of ARE-mRNAs
(17–24). ARE-mRNAs appear to be delivered to
P-bodies and subjected to translational repression and
mRNA decay by proteins including Tristetraprolin
(TTP) and BRF-1 (25). However, little is known about
the involvement of small GTPases in the P-body
dynamics and/or in the effective ARE-mRNA degrad-
ation under stress conditions.
In the present study, we have found that glucose deple-
tion alters P-body dynamics through activation of the
RhoA subfamily GTPases (RhoA, RhoB and RhoC).
These GTPases are inﬂuential regulators of signaling
pathways that control a wide range of cellular responses
including cytoskeletal organization (26–29). We set out to
investigate the roles of RhoA activation in regulating
P-body dynamics and mRNA metabolism by monitoring
TTP protein and the localization and degradation of
ARE-mRNAs in mammalian cells. The signaling
pathway used under stressed cellular conditions could
play an important role in rearranging P-bodies and in pre-
venting rapid degradation of ARE-mRNAs, such as inter-
leukins and cytokines.
MATERIALS AND METHODS
Cell culture, transfection and glucose depletion
HeLa and NIH3T3 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal
calf serum, 0.16% (w/v) NaHCO3, 0.6mg/ml L-glutamine,
100mg/ml streptomycin and 100IU/ml penicillin at 37 C
in 95% air and 5% CO2. The cells were transfected with
1mg (35mm dish) or 3mg (60mm dish) of plasmid DNA
using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA,
USA) or with 100pmol (60mm dish) of siRNA using
LipofectAMINE RNAiMAX (Invitrogen). Cells were
rinsed three times with phosphate-buffered saline (PBS)
and exposed to a glucose-free medium (Invitrogen) con-
taining 10% fetal bovine serum further supplemented with
or without glucose (the ﬁnal concentration of 1mg/ml).
Construction of plasmids
Open reading frames encoding RhoA, RhoB, RhoC,
Rac1, Cdc42, Rhotekin-RBD and TTP were ampliﬁed
by polymerase chain reaction (PCR) using human
whole-brain cDNA (Clontech, Mountain View, CA,
USA) and cloned into pCMV5-Myc (described previous-
ly) (30), pCMV-FLAG (replaced FLAG tag into Myc tag
position) or pGEX-6P (Clonetech). Dcp1a was also
isolated by PCR using human whole-brain cDNA and
cloned into pEGFP or pDsRed-monomer (Clontech).
The point-mutated forms of RhoA (G14V and T19N)
were isolated by one-day PCR as previously described
(31). pEF-b-globin-ARE was cloned by one-day PCR
using pEF-b-globin-MS2 (a generous gift from Paul
Anderson). The inserted ARE sequence of the GM-CSF
30-UTR was previously indicated (32).
RNA interference
HeLa cells were transfected with the Stealth
TM
siRNA
duplex oligonucleotides composed of 50-CAG GUA
GAG UUG GCU UUG UGG GAC A-30/50-UGU CCC
ACA AAG CCA ACU CUA CCU G-30 (154–178nt,
AF498970-#7, designed by Block-iT
TM
RNAi Designer
siRNA; Invitrogen) for RhoA knockdown or Stealth
RNAi negative control (Invitrogen) as a control dsRNA
using Lipofectamine RNAiMAX. After incubation for 48
h, the cells were utilized in experiments.
Antibodies
The antibodies used were anti-RhoA (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-rck/p54
(Novus Biologicals, Littleton, CO, USA) polyclonal
antibody,
anti-glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) (Millipore Bedford, MA, USA) and anti-Myc
(9E10; Sigma, St Louis, MO, USA) monoclonal
antibodies.
Immunoﬂuorescence study and microscopic observation
HeLa cells transiently expressing Myc-tagged proteins
were cultured on a poly-L-lysine-coated cover glass
(15-mm diameter) and washed three times with PBS,
followed by ﬁxation with 4% paraformaldehyde in PBS
at 25 C for 15min. After permeabilization with 0.02%
Triton X-100 in PBS for 10min, the cells were incubated
with a blocking solution consisting of 2% bovine serum
albumin and 2% fetal calf serum in PBS for 30min,
followed by incubation with the indicated antibodies
(1mg/ml diluted with blocking solution) at 37 C for 2h
(33). The cells were washed three times with PBS and
incubated for 1h with mouse Alexa-488- or
Alexa-568-conjugated secondary antibodies (Molecular
Probes, Eugene, OR, USA) diluted in blocking solution.
After washing further three times with PBS, the coverglass
was mounted onto a glass slide in Permaﬂuor mounting
medium (Immunon, Pittsburgh, PA, USA). The images
were viewed on a Carl Zeiss confocal microscope with
LSM510 software (Carl Zeiss, Jena, Germany) and
merged using Adobe Photoshop (Adobe Systems,
Mountain View, CA, USA). Cell nuclei were stained
with DAPI (Molecular Probes). For the estimation of
P-body numbers, the images stained with an anti-rck/
p54 antibody were captured using the Axio imager M1
(Carl Zeiss) to count the whole P-bodies in the cells.
Approximately 150 transfected cells were blindly scored
for the presence or absence of P-bodies by visual
examination.
Time-lapse microscopic analysis
The subcellular movement of eGFP-Dcp1a in HeLa cells
was obtained by using a confocal system (Yokogawa
CSU-10 spinning disk scanhead, Tokyo, Japan) attached
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Japan). The ﬂuorescence was recorded by an iXon
Electron Multiplying CCD (Andor Technology, Belfast,
Northern Ireland) using NIS element software. A
through-focus z-stack was recorded from the bottom to
the top of the cells. The z-stack interval was 0.6mm and
the resulting raw data set was Maximum Intensity
Projection reconstructed as a movie. Images were
acquired by a 59ms exposure every 1min. Cells were
rinsed three times with PBS and exposed to the
glucose-free medium containing 10% fetal bovine serum
at time 0.
Assay for GTP-bound RhoA GTPase
The GTP-bound form of RhoA was detected by a
pull-down assay with the glutathione S-transferase
(GST)-conjugated RhoA-binding domain of Rhotekin
(RBD) (34). Brieﬂy, the cells were washed with PBS and
lysed in a buffer consisting of 50mM Tris–HCl, (pH 7.5),
1% (w/v) Triton X-100, 100mM NaCl, 5mM MgCl2,
50mM NaF, 1mM Na3VO4, 1mM DTT, 0.5mM 4-
(2-aminoethyl)-benzenesulfonyl-ﬂonyl-ﬂouride (Pefabloc
SC, Roche, Indianapolis, IN, USA), 1.7mg/ml aprotinin
and 10% (w/v) glycerol. After centrifugation at 15
000rpm for 5min at 4 C, the supernatants were incubated
at 4 C for 30min with glutathione-Sepharose beads
coupled to GST-RBD. The beads were washed three
times with PBS containing 0.1% (w/v) Triton X-100,
5mM MgCl2 and 1mM DTT. The amount of total and
GTP-bound Rho GTPases was detected by Western
blotting with a polyclonal antibody against RhoA (1:500
dilution). Immunoblotting was performed as described
previously (33).
In situ-hybridization assay
In situ hybridization experiments were performed as
follows. The cells were transfected with reporter mRNA
expression plasmid and pDsRed-monomer-Dcp1a.
Twenty-four hours after transfection, cells were washed
with PBS, ﬁxed in 4% paraformaldehyde for 15min and
incubated in 0.1M triethanolamine with acetic anhydrid.
The cells were permeabilized in 0.2M HCl, and incubated
overnight at 37 C in a hybridization buffer (containing
50% formamide, 5  SSC, 0.1% Tween-20, 5mg/ml total
yeast RNA and 50mg/ml heparin). To detect the localiza-
tion of the b-globin-ARE mRNA, FITC-labeled 48-nt
DNA oligo probes (Invitrogen) complementary to se-
quences in the b-globin ORF were also added to the hy-
bridization buffer at a concentration of 200ng/ml and
incubated overnight. The cells were washed twice for
10min at 37 C in 50% formamide diluted in 2  SSC
prior to visualization.
Immunoprecipitation
HeLa cells were lysed in a homogenization buffer consist-
ing of 50mM Tris–HCl (pH 8.0), 100mM NaCl, 1%
Triton-X, 1mM EDTA, 1mM DTT, 500mM4 -
(2-aminoethyl)-benzenesulfonyl-ﬂonyl-ﬂouride (Pefabloc
SC, Roche) and 2mg/ml aprotinin. Cell lysates were
precleared with Protein G Sepharose (GE healthcare,
Buckinghamshire, UK) and incubated with anti-FLAG
M2 Agarose (Sigma) at 4 C for 2h. The beads were
washed three times with a wash buffer consisting of
50mM Tris–HCl (pH 8.0), 150mM NaCl, 0.7%
Triton-X, 1mM EDTA and 1mM DTT and eluted with
FLAG peptide (Sigma) in the wash buffer for 30min.
Supernatants containing immunoprecipitated FLAG-
tagged proteins were boiled and fractionated (along with
samples of the original lysate) by SDS–PAGE. Proteins of
interest were identiﬁed by immunoblotting with the appro-
priate antibodies. Immunoblotting was performed as
described previously (33).
Northern blot analysis
NIH3T3 cells were transiently transfected with
pEF-b-globin-ARE. After 24h, the cells were treated
with 5mg/ml Actinomycin D to inhibit transcription and
harvested at the indicated times. Total RNA was isolated
with Sepasol(R) (Nacalai Tesque, Kyoto, Japan) and
separated on a 1.2% (w/v) agarose gel by electrophoresis
using a NorthernMax Kit (Ambion, Huntingdon,
Cambridgeshire, UK). b-Globin-ARE mRNA was
detected by northern blotting using [
32P]-labeled b-globin
ORF as a probe. The labeled probes for b-globin-ARE
mRNA were prepared using the cDNAs of the coding
sequences for b-globin and Rediprime II Random Prime
Labelling System (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) according to the manufacturer’s
instructions. Hybridization was carried out in the
ULTRAHyb (Ambion) in the presence of
32P-cDNA
probes. The membrane was washed twice with 2  SSC
(1  SSC consists of 0.15M NaCl, 0.015M sodium
citrate) at 25 C, and twice with 1  SSC at 37 C. The
membrane was visualized by autoradiography. GAPDH
mRNA was used as an internal loading control.
All experiments were repeated at least three times with
different batches of cell samples and all the results were
fully reproducible.
RESULTS
Glucose depletion not only alters P-body dynamics but
also activates RhoA GTPase
Recent studies have revealed that glucose depletion leads
to a marked increase in P-body numbers in yeast cells (11).
We conﬁrmed such an increase, when HeLa cells were
incubated in a glucose-depleted medium (Figure 1A).
The stimulatory effect of glucose depletion is concomitant
with the formation of small P-bodies. We evaluated the
dynamics of P-bodies by ﬁrst monitoring an endogenous
marker protein, rck/p54, which is known to be required
for the formation of P-bodies (13). Since the target of
rapamycin (TOR) and its downstream GTPase, RhoA,
appear to be responsible for limiting protein synthesis
and cell growth during cell stress such as glucose depletion
(35), we examined the relationship between the effect of
glucose depletion on P-body dynamics and the activation
states of the Rho-subfamily GTPase in detail. HeLa cells
were incubated without glucose, and GTP-bound RhoA in
the cells was measured by its ability to bind to the RhoA
3448 Nucleic Acids Research, 2011,Vol.39, No. 8effector Rhotekin-RBD (Figure 1B), together with the
increase in P-body numbers (Figure 1C). The average
number of P-bodies per cell progressively increased by
 3-fold at 6h after glucose deprivation. There was also
a transient increase in GTP-bound RhoA, and the
maximum level was observed at earlier time (2h) than
that observed in the maximum number of P-bodies.
There was no signiﬁcant change in the amount of en-
dogenous rck/p54 during the various incubation times
(Figure 1B, the lowest panel), indicating that the
turnover of rck/p54 in P-bodies was not altered by
glucose depletion. We analyzed the effect of glucose de-
pletion on the P-body dynamics using live-cell imaging
with exogenously expressed GFP-Dcp1a (Figure 1D).
Glucose depletion induced a marked increase in the
number of GFP-Dcp1a-positive foci (also see
Supplementary Video S1). Live cell imaging suggests
that the increase in P-body number appears to be a
result of the formation of new P-bodies in the cytoplasm
and not from the division of previously formed P-bodies
(Supplementary Video S1). Thus, the activation of RhoA
appears to correlate with the alteration of P-body
dynamics.
GTP-bound forms of RhoA subfamily speciﬁcally alter
P-body dynamics
In order to determine the role of RhoA activation in the
alteration of P-body dynamics, ectopic expression of
various RhoA forms was introduced into HeLa cells.
When wild-type RhoA (RhoA/WT) was solely
over-expressed, there was a marked increase in the
number of small rck/p54-positive P-bodies (Figure 2A,
panel d, see the transfected cells surrounded by dotted
lines). A RhoA/G14V mutant (GTP-bound active form)
was also capable of stimulating P-body formation
(Figure 2A, panel f), but a RhoA/T19N mutant
(GDP-bound inactive form) did not stimulate the
creation of P-bodies (Figure 2A, panel h) (36,37). To de-
termine the functional differences among the Rho/Rac/
Cdc42 superfamily, other Rho GTPases were also
Figure 1. Glucose depletion alters P-body dynamics and activates RhoA. HeLa cells were incubated with a glucose-depleted medium for 4h (A)o r
the indicated times (B–D). (A) The cells were stained with an anti-rck/p54 antibody to detect the localization of endogenous rck/p54 (green), and cell
nuclei were stained with DAPI (blue). Merged images are also represented. (B) HeLa cells that had been incubated without glucose for the indicated
times were harvested, and the GTP-bound form of endogenous RhoA was quantiﬁed by a pulldown assay using the GST-conjugated RhoA-binding
domain of Rhotekin (GST-RBD). RhoA in the total cell lysates (input) was analysed by immunoblotting with an anti-RhoA antibody. Protein
amounts of GAPDH and rck/p54 in the cells were also quantiﬁed by immunoblotting with their speciﬁc antibodies (input). (C) The intensity of the
GTP-bound and total RhoA in Figure 1B was densitometrically analyzed, and the relative ratio of GTP-bound RhoA is shown by closed circles as
the fold stimulation of the 0-time value. The number of rck/p54-positive P-bodies per cell, which was counted in approximately 150 cells, is shown by
open circles. Results are presented as the mean±SE obtained from three separate experiments. (D) Live cell images of exogenously expressed
GFP-Dcp1a (20-min intervals) were obtained after glucose depletion. The number of P-bodies in the two indicated cells is shown in parentheses.
Scale bars indicate 20mm.
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have structural and functional similarities to RhoA, were
capable of stimulating P-body formation (Figure 2B,
panels b and d). However, Rac1 or Cdc42, which belong
to another Rho subfamily, does not noticeably alter the
dynamics of rck/p54-positive P-bodies (Figure 2C, panels
b and d). The effects of these Rho-family GTPases on
P-body dynamics are summarized in Figure 2D. These
results indicate that the GTP-bound forms of RhoA–C,
members of the RhoA-subfamily, are sufﬁcient for
inducing small P-body formation, and only the
RhoA-subfamily has speciﬁc effects on the dynamics of
P-bodies. To conﬁrm that activation of the RhoA subfam-
ily is responsible for the glucose-depleted effect on
P-bodies, we introduced Rhotekin/RBD into HeLa cells.
Rhotekin/RBD is capable of binding to GTP-bound
active forms of Rho GTPases thereby speciﬁcally inhibit-
ing the Rho-dependent signaling pathway (38). In cells
expressing Rhotekin/RBD (RhoA-binding domain),
glucose depletion failed to stimulate P-body formation
(Figure 2E and F). This ﬁnding indicates that activation
of the RhoA subfamily is required for the glucose-depleted
effect on P-body dynamics.
Since the expression of the RhoA subfamily markedly
altered the dynamics of rck/p54-positive foci, we further
investigated whether the small rck/p54-positive P-bodies
induced by RhoA have similar components to those in
non-transfected cells. HeLa cells were transfected with
an expression vector encoding GFP-Dcp1a. The
P-bodies containing endogenous rck/p54 were observed
to be well co-localized with the GFP signals in the
mock-transfected control cells (Supplementary Figure
S1, panel c). The increased rck/p54-positive P-bodies,
characteristic of RhoA-expressing cells, completely
merged with GFP-Dcp1a in RhoA-transfected cells
(Supplementary Figure S1, panel f). These results
indicate that P-bodies identiﬁed under both control and
RhoA-expressing conditions are similar to one another, at
least in terms of their constituent proteins, rck/p54 and
Dcp1a.
RhoA activation and glucose depletion impair the
nucleation of ARE-mRNAs into P-bodies
AREs are found in the 30-untranslated region of many
mRNAs which undergo translational silencing and rapid
decay. The accumulation of ARE-mRNAs in P-bodies is
Figure 2. GTP-bound RhoA subfamily speciﬁcally alters P-body dynamics. (A–C) HeLa cells were transiently transfected with Myc-mock,
Myc-RhoA/WT, Myc-RhoA/G14V, Myc-RhoA/T19N (A); Myc-RhoB/WT, Myc-RhoC/WT (B); Myc-Rac1/WT or Myc-Cdc42/WT (C) and
cultured for 24h. The expressed proteins were stained with an anti-Myc antibody (red). The localization of endogenous rck/p54 was determined
by immunoblotting with the anti-rck/p54 antibody (green). The transfected cells are surrounded by dotted lines. Scale bars indicate 20mm. (D) The
number of rck/p54-positive P-bodies per cell was counted in approximately 150 cells expressing the various forms of the Rho subfamily. Results are
presented as the mean±SE obtained from three separate experiments. (E and F) HeLa cells that had been transfected with Myc-Rhotekin/RBD
were cultured for 24h and further incubated with or without glucose for 4h. The localization of endogenous rck/p54 was determined with the
anti-rck/p54 antibody (E, green). The transfected and non-transfected cells are surrounded by dotted and solid lines, respectively. The number of rck/
p54-positive P-bodies per cell was counted in approximately 150 cells expressing the Rhotekin/RBD (F).
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hibited (25). These data suggest that P-bodies may
function as reservoirs, sequestering ARE-mRNAs from
polysomes to facilitate their decay effectively. We
investigated how intracellular localization of
ARE-mRNAs was modiﬁed by the RhoA-induced re-
arrangement of P-bodies. In the present assay, the ARE
of GM-CSF was chosen, since it is a well-deﬁned target of
rapid decay. The b-globin reporter mRNA containing the
GM-CSF ARE was expressed in HeLa cells and subjected
to in situ hybridization. Dcp1a fused to the reporter
molecule DsRed-monomer was used as a marker for the
localization of P-bodies. The in situ hybridization assay
clearly indicates that b-globin-ARE mRNA was
co-localized with foci containing Dcp1a (Figure 3A),
indicating that the ARE-mRNA is nucleated into the
intact P-bodies to serve as substrates of decay enzymes
under glucose-loaded normal conditions. However, the
ARE-mRNA was also localized in the cytoplasm, in
addition to the rearranged Dcp1a-positive P-bodies,
when the HeLa cells had been transfected with RhoA/
WT (Figure 3B). Furthermore, the localization of
ARE-mRNAs was evident in the cytoplasm, along with
Dcp1a-positive P-bodies, under glucose-depleted condi-
tions (Figure 3C).
Glucose depletion and RhoA activation diminish TTP
protein and impair the rapid degradation of ARE-mRNAs
Previous study has shown that TTP targets ARE-mRNAs
to P-bodies for their translational silencing (25). We there-
fore investigated whether glucose depletion and RhoA ac-
tivation exerted their inﬂuence on the amount of TTP
protein. Endogenous TTP protein in HeLa cells could
not been detected by using several antibodies commercial-
ly available (data not shown). Therefore, CMV-drived
FLAG-tagged TTP was introduced into HeLa cells, and
the cells were further incubated with or without glucose.
As shown in Figure 4, there was progressive decrease in
the protein level of TTP upon glucose depletion
(Figure 4A, lanes 1–3 versus 4 and B). Furthermore,
Figure 3. RhoA activation and glucose depletion impair the nucleation of ARE-mRNAs into P-bodies. (A and B) HeLa cells that had been
transfected with b-globin-ARE mRNA, DsRed-monomer-Dcp1a and either Myc-mock (A) or Myc-RhoA/WT (B) were cultured for 24h.
(C) HeLa cells that had been transfected with b-globin-ARE mRNA and DsRed-monomer-Dcp1a were cultured for 24h and further incubated
without glucose for 4h. The b-globin-ARE mRNA was detected by in situ hybridization using a FITC-conjugated anti-sense oligonucleotide for the
b-globin ORF. b-globin-ARE mRNA (green; panel a), DsRed-monomer-Dcp1a (red; panel b) and merged images (panel c) are shown. Individual
cells are surrounded by dotted lines. Scale bars indicate 10mm.
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ished TTP protein without the cell exposure to
glucose-depleted medium (Figure 4C, lanes 1–3 versus
5–7). Importantly, the reduction of the protein amount
of TTP protein by glucose depletion was clearly abolished
with the addition of glucose (Figure 4A, lane 4 and C,
lanes 4 and 8), and these results are consistent with low
expression of TTP under SV40 promoter and terminator
(data not shown).
RhoA activation by glucose depletion impair the rapid
degradation of ARE-mRNAs
We next investigated how the P-body alteration induced
by RhoA and glucose depletion affected the degradation
rate of b-globin-ARE mRNA. Actinomycin D was used to
shut down transcription, and subsequent mRNA degrad-
ation was monitored by northern blot analysis. The
reporter ARE-mRNA was rapidly degraded in the
control NIH3T3 cells that had been transfected with a
mock plasmid (Figure 5A, upper lanes 1–3).
Over-expression of RhoA/WT markedly reduced the deg-
radation rate of the reporter mRNA (Figure 5A, upper
lanes 4–6). The rapid degradation of b-globin-ARE
mRNA was also impaired under glucose-depleted condi-
tions (Figure 5B, upper lanes 4–6). As expected,
b-globin-MS2 mRNA lacking the ARE (Figure 5C,
upper panels) remained stable throughout Actinomycin
D treatment, and RhoA over-expression or glucose deple-
tion did not alter their degradation rate.
RhoA protein itself is essentially required for P-body
formation
We also performed knockdown of endogenous RhoA with
siRNA to conﬁrm the requirement of RhoA for the
glucose depletion-induced alteration of P-bodies.
Immunoblot analysis indicated that treatment with
RhoA-siRNA was very effective in reducing the endogen-
ous protein and that glucose depletion did not alter the
diminished RhoA level (Figure 6A). Surprisingly, there
was no P-body formation in the RhoA-knockdown cells
even under glucose-loaded control conditions, and glucose
depletion failed to stimulate P-body formation (Figure 6B
and C). The re-introduction of silent-mutated RhoA at the
siRNA target site recovered the formation of P-bodies
(Supplementary Figure S2A and B), indicating that the
loss of P-bodies with RhoA-siRNA was certainly due to
reducing the level of RhoA. Introduction of RhoA with
silent mutations conferred resistance to RNA interference
as expected (Supplementary Figure S2C). Thus, RhoA
protein itself appears to be essentially required for
P-body formation.
Figure 4. RhoA activation and glucose depletion diminish the protein amount of TTP. HeLa cells that had been transfected with FLAG-TTP (A)
and further with either Myc-mock (C, lanes 1–4) or Myc-RhoA/WT (C, lanes 5–8) were cultured for 24h. The cells were further incubated with or
without glucose for the indicated times. Lysates and proteins immunoprecipitated with anti-FLAG beads were subjected to immunoblot analysis to
detect the indicated proteins. The intensity of proteins in (A) was densitometrically analyzed, and the relative ratio of TTP/GAPDH obtained from
three separate experiments is shown as the mean±SE as percentages of the 0-time value (B).
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sembly might be rather an unexpected phenotype, since
overexpression of the RhoA subfamily stimulated small
P-body formation, and since P-bodies with normal size
were still observed when RhoA activation had been in-
hibited by the expression of Rhotekin/RBD or the
dominant-negative RhoA/T19N mutant (Figure 2).
Therefore, we further investigated how P-body disassem-
bly induced by the RhoA knockdown exerted its inﬂuence
on the amount of TTP protein and the degradation of
ARE-mRNAs. As shown in Figure 6D, TTP protein
level was markedly decreased in RhoA-depleted cells
(Figure 6D, lanes 1 versus 2). Moreover, the rapid degrad-
ation of ARE-mRNAs was markedly impaired by RhoA
knockdown (Figure 6E, upper lanes 1–3 versus 4–6).
These results indicate that RhoA protein itself is
required not only for the formation of P-bodies but also
for rapid degradation of ARE-mRNAs.
DISCUSSION
In the present study, we ﬁnd that glucose depletion not
only alters P-body dynamics but also activates RhoA in
HeLa cells (Figure 1). Among Rho/Rac/Cdc42 super
family, the RhoA subfamily speciﬁcally alters the
P-body dynamics, and inhibition of the RhoA-subfamily
activation abolishes the glucose-depleted effect on P-body
dynamics (Figure 2). Importantly, both glucose depletion
and RhoA activation diminish TTP protein (Figure 4) and
inhibit the nucleation of ARE-mRNAs into the
rearranged P-bodies and their degradation (Figures 3
and 5). Moreover, the loss of TTP protein and the
impaired degradation of ARE-mRNAs were also
observed in P-body-disassembled cells induced by RhoA
knockdown (Figure 6). Although it is well known that the
RhoA-subfamily small GTPase regulates a wide range of
cellular responses, this is the ﬁrst report demonstrating
that activation of the RhoA subfamily is involved in the
stress-induced rearrangement of P-bodies and the release
of nucleated ARE-mRNAs.
Signiﬁcance of the rearranged P-bodies created by
RhoA activation
The size and number of P-bodies in glucose-depleted or
RhoA-expressing cells appear to be microscopically
smaller than those in the steady-state HeLa cells. The
small P-bodies created by RhoA activation contain two
P-body marker proteins, rck/p54 and Dcp1a, and the
microscopic images indicate that their co-localization is
undistinguishable from that in control cells
(Supplementary Figure S1). Core components of P-body
formation and also some mRNA decay machinery are still
present in the rearranged small P-bodies. According to an
estimate of the rck/p54- or Dcp1a-immunostained density
of P-bodies, their total volumes per single cell may be
almost constant, in spite of the alteration of P-body
dynamics (data not shown). Moreover, we show a
marked decrease of P-bodies in cells where RhoA has
been knocked down (Figure 6B and C). Re-introduction
of a wild-type RhoA-siRNA resistant mutant could
re-organize the P-body (Supplementary Figure S2A and
B). These results indicate that RhoA is essentially required
for P-body formation. Assuming that the total mass of the
P-body component remains the same, the components of
P-bodies in RhoA-knockdown cells are nearly diffused
and invisible in cytoplasm. This indicates that phenotypes
of overexpression and knockdown might go partly in the
same direction. Supportively, both RhoA overexpression
and knockdown on the decrease of TTP protein level
under glucose depletion and the stabilization of
ARE-mRNAs are rather similar (Figures 3–6). It thus
seems likely that the balance between activated RhoA
and inactivated RhoA is precisely regulated and that
RhoA activation and RhoA knockdown might result in
Figure 5. RhoA activation and glucose depletion impair the rapid deg-
radation of ARE-mRNAs. NIH3T3 cells that had been transfected with
b-globin-ARE mRNA (A and B)o rb-globin-MS2 mRNA (C) and
Myc-mock (A and C, left panels) or Myc-RhoA/WT (A and C, right
panels) were cultured for 24h. The transfected cells were also further
incubated with (B, lanes 1–3) or without (B, lanes 4–6) glucose for 4h.
These cells were treated with Actinomycin D (ActD) to inhibit tran-
scription and further incubated for the indicated times. Total RNA was
extracted from the cells and subjected to northern blot analysis to
estimate the amounts of b-globin-ARE mRNA (A and B) and
b-globin-MS2 mRNA (C). GAPDH mRNA was used as a loading
control.
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tion of ARE-mRNAs. It has been established that
Rho-family GTPases regulate primarily cytoskeletal re-
organization in response to extracellular signals in mam-
malian cells. Indeed, microtubule disruption leads to a
decrease of P-body mobility and an increase in P-body
abundance (15). Concomitantly, we have examined
effects of microtubule disruption and observed that
nocodazole treatment has the similar effect on RhoA ac-
tivation and P-bodies dynamics as glucose depletion
(Supplementary Figure S3A and B). The nocodazole-
induced increase of P-bodies is inhibited by
overexpression of Rhotekin/RBD (Supplementary
Figure S3C and D). These ﬁndings suggest that the
glucose-depleted effects on P-body dynamics and
ARE-mRNA metabolism are linked to RhoA activation-
dependent cytoskeletal regulation. The live-cell imaging
during glucose depletion indicated that the increase in
small P-bodies is not due to the division of pre-existing
large P-bodies (Supplementary Movie S1). These ﬁndings
suggest that a key component(s) required for P-body for-
mation is diffusely distributed as cytoplasmic pool and
that rearrangement of P-bodies is properly induced de-
pending on cellular conditions. Based on this assumption,
it can be speculated that aggregation into large P-bodies
provides a mechanism to effectively increase the local con-
centrations of mRNA substrates. Indeed, catalytic
enzymes of mRNA decay, hDcp2 and hXrn1, are
Figure 6. The effects of RhoA knockdown on P-body formation and the degradation of ARE-mRNAs. (A–C) HeLa cells that had been transfected
with RhoA-speciﬁc siRNA or control siRNA were cultured for 48h and further incubated with or without glucose for 4h. The cells were subjected to
immunoblot analysis with the indicated antibodies (A). Localization of endogenous rck/p54 in the treated cells was determined with the anti-rck/p54
antibody (B, green). The cells are surrounded by dotted lines. Scale bars indicate 10mm. The number of rck/p54-positive P-bodies per cell was
counted in approximately 150 cells (C). Results are presented as the mean±SE obtained from three separated experiments. (D) HeLa cells that had
been transfected with RhoA-speciﬁc siRNA or control siRNA were further transfected with FLAG-TTP and cultured for 24h. Lysates and proteins
immunoprecipitated with anti-FLAG beads were subjected to immunoblot analysis to detect the indicated proteins. (E) NIH3T3 cells that had been
transfected with RhoA-speciﬁc siRNA or control siRNA were cultured for 24h were further transfected with b-globin-ARE mRNA. The cells were
treated with Actinomycin D (ActD) to inhibit transcription and further incubated for the indicated times. The amount of b-globin-ARE mRNA was
measured as described in Figure 5.
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results in accumulation of ARE-mRNAs in P-bodies
lacking the decay activity (25).
Proposed mechanisms for RhoA activation and P-body
rearrangement
In this study, inhibition of the Rho-dependent signaling by
means of Rhotekin/RBD overexpression inhibits P-body
formation under glucose depletion (Figure 2E). However,
a dominant-negative form of RhoA (RhoA/T19N) or
Rhotekin/RBD fails to alter the number of P-bodies
under non-stressed conditions (Figure 2A and E). We
show that RhoA exists as a slightly activated
(GTP-bound) state and that further activation occurs
under conditions of cellular stress (Figure 1B). The expres-
sion of RhoA/T19N and Rhotekin/RBD was not able to
fully suppress the Rho-dependent pathway, suggesting
that slightly activated RhoA and its effector may be suf-
ﬁcient at least for organizing P-bodies (Figure 2A and E).
During glucose depletion, Rhotekin/RBD inhibits further
RhoA activation, and therefore the number of P-bodies
could not increase. Alternatively, we propose the notion
that another compensated pathway for the P-body forma-
tion is activated during RhoA suppression under
steady-state conditions. The rearrangement pathway for
P-bodies may be stimulated by Rho and/or signaling
proteins, which are activated by the internal cell cycle or
the external environment.
The large families of guanine nucleotide-exchange
factors (GEFs) and GTPase-activating proteins (GAPs)
play roles in regulating Rho activity, in response to
cellular stress, but upstream and speciﬁc targets for the
rearrangement of P-bodies remain unclear in the present
study. We have examined overexpression of ROCK, mDia
and Smurf as the possible downstream effectors of Rho
GTPase on the organization of P-bodies, but their
overexpression did not affect the P-body dynamics. An
additional study to identify the Rho effectors is required
to deﬁne the molecular mechanisms for the stress-induced
P-body rearrangement.
Relationship between the RhoA-induced rearrangement of
P-bodies and ARE-mRNA decay and translation
Recent studies show that P-body formation is not causa-
tive of neither rate-limiting for general mRNA decay
(6,39–41) nor miRNA-mediated translational control
(42,43) in P-body component-knockdown cells. In yeast
cells, P-bodies may not be the predominating sites for
general mRNA decapping (44). We hypothesize that
ARE-mRNA decay is a special case. ARE-mRNAs are
speciﬁcally delivered to P-bodies and subjected to transla-
tional repression by proteins including TTP (25). This
suggests that inhibition and/or degradation of TTP
induce mislocalization of ARE-mRNAs. In the present
study, we observe that both glucose depletion and RhoA
activation diminish exogenous TTP protein and inhibit the
nucleation of ARE-mRNAs into the rearranged P-bodies
(Figures 3 and 4). These results conﬁrm the notion that
TTP protein regulates localization of ARE-mRNAs. The
reduction of TTP was also observed with two different
promoters for the exogenous protein, suggesting that the
TTP reduction is attributed to post-transcription, not to
promoter or terminator. We tested whether TTP might be
proteolysed under glucose-depleted conditions, however,
addition of a proteasome inhibitor (MG132) or a revers-
ible inhibitor of serine and cysteine proteases (leupeptin)
did not inhibit the TTP reduction (data not shown).
Further investigations are necessary to elucidate the mo-
lecular mechanism of TTP down-regulation. The degrad-
ation of ARE-mRNAs is impaired in cells with both
overexpression and knockdown of RhoA. Although
P-body formation appears to link to ARE-mRNA metab-
olism (7,25), the requirement of their localization in
P-bodies for rapid degradation has not been fully under-
stood. Our present ﬁndings that mislocalized
ARE-mRNAs in cytoplasm are escaped from efﬁcient
degradation shed light on this question (Figures 3 and 5).
It is interesting to consider Rho GTPase activation with
respect to speciﬁc aspects of ARE-mRNA metabolism and
translation. Pro-inﬂammatory proteins such as TNF-a,
GM-CSF and cyclooxygenase-2 are encoded by
short-lived mRNAs that are inefﬁciently translated
(17,32,45–47). The protein products of these mRNAs are
barely detectable under steady-state conditions, although
cell stimulation leads to expression of these proteins.
Several reports support this idea (48–51) as the stimuli
used in these experiments have been reported to activate
the Rho-family GTPases (52,53). We expected elevated
ARE-mRNAs to be translated efﬁciently, however,
increase of exogenously transfected ARE-mRNAs was
not apparently detected in both control and
RhoA-activated cells (data not shown). These results sug-
gested that the reporter ARE-mRNAs released from
P-bodies might be translationally silent under the
present assay conditions. RhoA activation may be insuf-
ﬁcient for the translational stimulation of ARE-mRNAs,
and trans-acting factors, such as TIA-1 and TIAR, might
be involved in the translational regulation of
ARE-mRNAs. These important issues are currently
under investigation in our laboratory.
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